Impact of clinical response and treatment tolerability on HRQoL in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia patients treated with ponatinib or imatinib.

ABSTRACT: In the phase 3 PhALLCON trial (NCT03589326), ponatinib demonstrated superior efficacy, patient-reported treatment tolerability, and health-related quality of life (HRQoL) compared to imatinib in adults with newly diagnosed Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). To explore the association between clinical response and HRQoL and substantiate the superior effect of ponatinib over imatinib on HRQoL, we analyzed the impact of clinical response and treatment tolerability on changes in HRQoL.HRQoL was assessed using the Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu) questionnaire and the EQ-5D-5 L. Treatment tolerability was assessed using the FACT-GP5 item "bothered by treatment side effects." Linear mixed-effects regression models were used to ex

SUBMITTER: Ashaye A 

PROVIDER: S-EPMC12552232 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature